2017 performance forecast of pharmaceutical listed companies shows that the net profit of these enterprises is expected to be more than 1 billion

Recently, according to incomplete statistics of network data, in the 2017 performance forecast released by Listed Medical and health companies, there are already 8 companies with annual net profit of more than 1 billion yuan, involving Shanghai Laishi, xinlitai, jiankangyuan, Lizhu group, Bikang, Ruikang medical, XinHeCheng and Yifan medical Figure 1 Shanghai Laishi, an enterprise with a estimated net profit of more than 1 billion in 2017 - Shanghai Laishi, a large blood products company, expects that its net profit in 2017 will not fluctuate much compared with the same period of last year, and the change range of performance is about - 15% - 15% Shanghai Laishi blood products Co., Ltd was founded in 1988 Its main products include 11 products of three categories: human blood protein, human immunoglobulin and coagulation factor It has won the bid in 19 regions in China (as shown in Figure 2) Shanghai Laishi has been registered in nearly 20 countries, and is one of the few domestic enterprises that can export blood products According to the company, Shanghai Laishi has 35 plasma stations under construction in China, with an annual production capacity of 900 tons of plasma and a total of more than 30 million bottles of products There has never been any confirmed report of virus infection and adverse events related to product quality In August 2017, Shanghai Laishi was rated as the fourth most innovative enterprise in the world by Forbes Figure 2 product situation of Shanghai Laishi xinlitai - xinlitai, a famous high-tech enterprise, expects its net profit in 2017 to be between 1.396-1.536 billion yuan, with an increase of about 0% - 10% compared with 1.396 billion yuan in the same period of last year The range is not large, but there is still a trend of growth Shenzhen xinlitai Pharmaceutical Co., Ltd was founded in November 1998, mainly engaged in the production and operation of chemical APIs, powder injection, tablets and capsules, etc it is a high-tech joint venture integrating R & D, production and sales In addition, xinlitai focuses on the development of national first and second class new drugs, mainly focusing on cardiovascular, anti infection, anti allergy and anti-tumor treatment fields, and research and development of pharmaceutical products with independent intellectual property rights Clopidogrel bisulfate tablets (TEGA) and desloratadine tablets (xinminting), two new class II drugs, are recognized as national key new products Clopidogrel bisulfate tablets were listed in the catalogue of Chinese drugs on the market in December 2017 In addition, according to drug intelligence data, xinlitai has 196 drug undertakers (calculated according to the acceptance number, the same below), including 50 new drugs, 17 clinical approval and 13 production approval Jiankangyuan - jiankangyuan, a national best enterprise, is expected to have a net profit of 2-2.1 billion yuan in 2017, an increase of 362% - 383% compared with the same period last year, which is a year with a significant increase in profit Jiankangyuan Pharmaceutical Group Co., Ltd was born on September 29, 2003 The group formerly known as wife Pharmaceutical Co., Ltd now jiankangyuan Pharmaceutical Group has developed into a professional comprehensive pharmaceutical enterprise covering four major fields, including API, OTC, prescription medicine and health care products The group has a number of modern large pharmaceutical industry bases that have passed the national GMP certification Some of its product lines, including madam oral liquid, Jingxin oral liquid, hawk brand ginseng, yiketie, zhengyuandan, have passed the GMP audit of the Australian drug administration (TGA) (equivalent to China's Drug Administration), and obtained the Australian GMP certification Products are exported to the United States, Australia, Singapore, Malaysia, Hong Kong, Macao and Taiwan Lizhu group, a well-known brand enterprise, expects its net profit in 2017 to be between 4.3-4.4 billion, an increase of 450% - 470% compared with the same period last year, which can be said to be a better year for profit Lizhu Pharmaceutical Group Co., Ltd is a comprehensive enterprise group integrating research and development, production and sales of medicine It was founded in January 1985 Zhuhai Lizhu McAb Biotechnology Co., Ltd., a holding subsidiary of the company, is a well-known McAb company in China, and Lizhu brand enjoys a good reputation in China The group now has 18 patented products and 21 exclusive products, among which Shenqifuzheng injection and iprazole have won the first prize of Guangdong Provincial Science and technology progress The company's products are distributed in many cities in China and win the bid in many places (as shown in Figure 3) In 2017, Lizhu brand ranked 318 in the top 500 brand values Figure 3 product situation of Lizhu Pharmaceutical Group Bikang Co., Ltd - the expected profit of large pharmaceutical enterprise Bikang Co., Ltd in 2017 is between 811-1097 million yuan, which is likely to be the same as 954 million yuan in the previous year, with a change range of - 15% - 15% Bikang has developed rapidly in recent years At present, in addition to the pharmaceutical sector, pharmaceutical intermediates (pharmaceutical intermediates, pesticide intermediates), there are also new energy and new materials sectors In the course of development, Bikang group has successively completed the investment and merger of Wuhan Wujing pharmaceutical, Jiangsu Kangbao pharmaceutical, Shaanxi jinweisha pharmaceutical, baojixin Zhongtian pharmaceutical, Xi'an Lingdan pharmaceutical, Xi'an Jiaotong University Pharmaceutical Group and Xi'an Jiaotong University Ruixin pharmaceutical Bikang group has developed into a modern large-scale pharmaceutical enterprise group integrating the research and development of APIs, Chinese patent medicines, chemicals, biological agents, vaccines, health products, health drinks production and marketing In July 2016, he was ranked 19th in the top 100 pharmaceutical industry of China in 2015 In 2017, the performance of Ruikang pharmaceutical, a famous pharmaceutical circulation enterprise, was 827-1124 million, with an increase of 40% - 90% compared with 591 million in the previous period Ruikang Pharmaceutical Co., Ltd was established in 2004, focusing on the pharmaceutical circulation industry In recent years, Ruikang pharmaceutical has developed rapidly In recent two years, with the control of the current situation, policy opportunities, business to value-added, two vote system, it has acquired 186 pharmaceutical, equipment, testing and other commercial companies nationwide, and completed the full coverage of more than 30 provincial administrative regions In addition, Ruikang's national expansion is not a simple merger and acquisition, but a copy of Shandong's direct sales model in all provinces of the country, the most important of which is to build a complete logistics information management system that has been formed for many years to connect with the provinces Ruikang has the ability to overtake in the new round of competition in the current pharmaceutical business According to the 2017 third quarter report of Ruikang pharmaceutical, the net profit in the first three quarters has reached 720 million yuan, which has increased compared with the 2016 net profit In 2017, we will receive gratifying results The 2017 performance of new Hecheng pharmaceutical and chemical brand new Hecheng is between 1433-1804 million, with an increase of 20% - 50% compared with the previous period's 1.203 billion As the first share of domestic SME board, XinHeCheng was founded in 1999 After the baptism of capital market, the market value of XinHeCheng changed from 402 million yuan at the beginning of listing to 27.5 billion yuan (October 11, 2017) The company is mainly engaged in fine chemicals, involving nutrients, flavors and fragrances, raw materials, polymers, new materials and other fields The new and nutritious plate has become a leading global position, and has become a series of large-scale international vitamin giant The market share of the company's various products is among the top three in the world, with strong market competitiveness and influence At the same time, PPS products developed by the company and DSM have been sold all over the world The flavor and fragrance plate has been the first in China, and has the conditions to maintain rapid growth At present, XinHeCheng has established a close cooperation relationship with leading enterprises in the industry at home and abroad, and has become a trusted and recognized brand of international famous pharmaceutical and cosmetics companies, and has become one of the top 100 pharmaceutical industry companies in China and one of the top 100 listed companies in China In recent years, XinHeCheng has not been satisfied with the status quo It has found another "big product" - methionine, and locked it into a new chip for reconstruction In 2017, affected by the environmental competition, after July, the prices of various products began to rise, and the growth of new hexeng performance became inevitable Yifan pharmaceutical - the sales capacity of jiayifan pharmaceutical in 2017 was between 1.163-1.374 billion, an increase of 65% - 95% compared with 748 million in the previous period The company is mainly engaged in the research and development, production and sales of pharmaceutical products, APIs and polymer materials Pharmaceutical products mainly include antibiotics, cardio cerebrovascular products, skin products, gynecology products, pediatrics products, blood tumor products, therapeutic infusion products, etc.; raw materials mainly include vitamin B5 and original B5 products; polymer materials mainly include PBS and PVB products In 2017, 11 exclusive products were newly included in the national medical insurance in 2017, and compound Huangdai tablets were included in the negotiation catalogue Before that, the acquisition and integration of the company has been completed, forming three major drug production centers in Shenyang, Chengdu and Anhui The company's pharmaceutical business covers all provinces, regions and cities except Hong Kong, Macao and Taiwan The coverage rate of pharmaceutical preparations in hospitals above the second level in China exceeds 60% The company is the world's largest manufacturer and supplier of vitamin B5 and provitamin B5 Its products sell well in the world, with a market share of about 40% Yifan pharmaceutical is good at sales, and its market share of ceftazidime, which is the total distributor of Hainan hailing, ranks first in the fierce competition With the implementation of the new national medical insurance in each province in 2017, the sales of preparations will usher in a big outbreak A number of products, such as oxytocin nasal spray, compound Huangdai tablets (with definite curative effect, leukemia Medication Guide), piminxiao capsule, fuyinkang lotion, xiaoerjinqiao granules, are expected to bring better profits to the company Data source: online public information data source: drug registration and acceptance database, drug winning information database, drug listing catalogue of China